Myeloma associated amyloidosis presenting as subacute liver failure 10.1136/pgmj.2006.044883 View in Scopus Google Scholar 17 J. Buzalewski, M. Fisher, R. Rambaran, R. Lopez Splenic rupture secondary to amyloid light-chain (AL) amyloidosis associated with multiple myeloma ...
Systemic kappa light chain deposition and amyloidosis in multiple myeloma: novel morphological observations. Histopathology 1986; 10: 1065-1076Kirkpatrick CJ, Curry A, Galle J, Melzner I (1986) Systemic kappa light chain deposition and amyloidosis in multiple my- eloma: novel morphological observations...
Want to thank TFD for its existence? Tell a friend about us, add a link to this page, or visit the webmaster's page for free fun content. Link to this page: LCMM Facebook Twitter Feedback Complete English Grammar Rules is now available in paperback and eBook formats...
A 68-year-old female patient with multiple myeloma exhibited advanced nodular glomerulosclerosis. Immunofluorescence of the kidney showed kappa light chain deposition in the mesangium and in glomerular and tubular basement membrane. Isoelectric focusing and immunofixation of urinary proteins revealed an isol...
Light chain only MCN: Myeloma cast nephropathy MM: Multiple myeloma MRC: Medical research council RI: Renal impairment ROC: Receiver operating curve rs : Spearmans coefficient SD: Standard Deviation References Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibili...
Objective To investigate the clinical value of urine κ/λ light chain in the diagnosis of multiple myeloma(MM).Methods The levels of urine κ/λ light chain from a total of 106 MM patients and 30 healthy controls were measured by immune rate nephelometry,so as to evaluate the clinical diagn...
www.nature.com/scientificreports OPEN CD4+CD25+ cells in multiple myeloma related renal impairment received: 28 June 2015 accepted: 15 October 2015 Published: 13 November 2015 Hongdong Huang1,2, Yang Luo1, Yumei Liang2, Xi-Dai Long3, Youming Peng4, Zhihua Liu1, Xiaojun...
Multiple myeloma (MM) remains an incurable hematological malignancy disease characterized by the progressive dysfunction of the patient’s immune system. In this context, immunotherapy for MM has emerged as a prominent area of research in recent years. Various targeted immunotherapy strategies, such as...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Introduction: Smoldering multiple myeloma (SMM) is an asymptomatic and biologically heterogeneous clonal plasma cell disorder. A number of prognostic factors to identify patients at a higher risk of progression have been described, such as the size of the M protein, proportion of abnormal bone marrow...